A retrospective real-world single center study assessing the immune related adverse effects cancer patients treated with immune checkpoint inhibitors
Latest Information Update: 01 Sep 2021
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Cancer; Gastrointestinal cancer; Head and neck cancer; Hodgkin's disease; Lung cancer; Malignant melanoma; Small cell lung cancer; Urogenital cancer
- Focus Adverse reactions
Most Recent Events
- 01 Sep 2021 Results published in the Journal of Cancer Research and Clinical Oncology
- 08 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology